Post neoadjuvant management in BRCA mutant breast cancer patients

Neoadjuvant Chemotherapy How It Shapes Breast Cancer SurgeryПодробнее

Neoadjuvant Talazoparib for BRCA 1/2 Mutated Triple Negative Breast CancerПодробнее

Breast Cancer Genetics: Clues to Tumor BiologyПодробнее

ASCO: Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patientsПодробнее

Adjuvant Therapy | 2023 Best of Breast ConferenceПодробнее

Emerging Options for BRCA-Mutated Breast Cancer TreatmentПодробнее

Residual tumor treatment in mutant BRCA-1 triple-negative breast cancerПодробнее

Treatment and Issues For Triple Negative Breast Cancer-May 14, 2020Подробнее

Dr. Litton on a Study of Neoadjuvant Talazoparib for Patients With BRCA-Mutated TNBCПодробнее

Neoadjuvant talazoparib active in BRCA-mutated early breast cancer | Jennifer LittonПодробнее

BRCA-Positive Early-stage Breast Cancer: Treatment and TestingПодробнее

Updates on the Treatment of BRCA-Associated Breast CancerПодробнее

Evaluation of Breast Specimens after Neoadjuvant ChemotherapyПодробнее

ClarifyingComplexities of ExpandingTreatmentOptionsFor AdvancedAndEarly-Stage HR+/HER2- BreastCancerПодробнее

ACTG Dinner Symposium Highlights | Beyond BRCA testing – does HRD matter? | Prof Michael FriedlanderПодробнее

Breast Cancer Neoadjuvant Chemotherapy: For PatientsПодробнее

Effectiveness of ICIs in the neoadjuvant and post-neoadjuvant breast cancer settingПодробнее

OlympiA: Adjuvant olaparib delays recurrence of BRCA-mutant breast cancer | Judy GarberПодробнее

Practical approach to the management of the axilla after neoadjuvant chemotherapyПодробнее

Triple Negative Breast Cancer: Predictive and Prognostic Biomarkers for Neo/Adjuvant TherapyПодробнее